

# Ettore D Argento

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1822234/ettore-dargento-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

38  
papers

466  
citations

13  
h-index

20  
g-index

44  
ext. papers

632  
ext. citations

3.8  
avg, IF

3.37  
L-index

#	Paper	IF	Citations
38	The Renaissance of KRAS Targeting in Advanced Non-Small-Cell Lung Cancer: New Opportunities Following Old Failures.. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 792385	5.3	0
37	Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. <i>Frontiers in Oncology</i> , <b>2021</b> , 11, 650293	5.3	4
36	Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study. <i>Cancer Immunology, Immunotherapy</i> , <b>2021</b> , 70, 1583-1592	7.4	4
35	Collagenous colitis and atezolizumab therapy: an atypical case. <i>Clinical Journal of Gastroenterology</i> , <b>2021</b> , 14, 165-169	1.1	3
34	Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of $\geq 50$ . <i>Cancer Immunology, Immunotherapy</i> , <b>2020</b> , 69, 2209-2221	7.4	32
33	Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. <i>Cancers</i> , <b>2020</b> , 12,	6.6	27
32	Immune-related Adverse Events of Pembrolizumab in a Large Real-world Cohort of Patients With NSCLC With a PD-L1 Expression $\geq 50\%$ and Their Relationship With Clinical Outcomes. <i>Clinical Lung Cancer</i> , <b>2020</b> , 21, 498-508.e2	4.9	27
31	Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study. <i>Lung Cancer</i> , <b>2020</b> , 150, 123-131	5.9	4
30	Malignant Pleural Mesothelioma: Is Tailoring the Second-Line Therapy Really "Raising the Bar?". <i>Current Treatment Options in Oncology</i> , <b>2019</b> , 20, 23	5.4	3
29	Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: case series and review of the literature. <i>Drugs in Context</i> , <b>2019</b> , 8, 212613	5.2	15
28	Listening understanding and acting (lung): focus on communicational issue in thoracic oncology.. <i>Translational Cancer Research</i> , <b>2019</b> , 8, S16-S22	0.3	
27	Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 3775-3782	3.6	4
26	Lung and Gut Microbiota as Potential Hidden Driver of Immunotherapy Efficacy in Lung Cancer. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 7652014	4.3	21
25	PD-L1 for selecting non-small-cell lung cancer patients for first-line immuno-chemotherapy combination: a systematic review and meta-analysis. <i>Immunotherapy</i> , <b>2019</b> , 11, 921-930	3.8	5
24	Impact of Exon 19 Deletion Subtypes in EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer Treated With First-Line Tyrosine Kinase Inhibitors. <i>Clinical Lung Cancer</i> , <b>2019</b> , 20, 82-87	4.9	11
23	Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis. <i>Pathology and Oncology Research</i> , <b>2019</b> , 25, 513-520	2.6	4
22	DEBIRI plus capecitabine: a treatment option for refractory liver-dominant metastases from colorectal cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 2349-2360	3.6	7

21	Does sarcopenia affect outcome in patients with non-small-cell lung cancer harboring EGFR mutations?. <i>Future Oncology</i> , <b>2018</b> , 14, 919-926	3.6	16
20	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. <i>Expert Opinion on Biological Therapy</i> , <b>2018</b> , 18, 937-945	5.4	10
19	Monoinstitutional real world experience in management of Vinflunine as second line therapy for transitional cell carcinoma of the urothelium. <i>Oncotarget</i> , <b>2018</b> , 9, 8765-8771	3.3	4
18	The interference between oxaliplatin & anti-EGFR therapies: a different hypothesis to explain the Unexplainable. <i>Personalized Medicine</i> , <b>2018</b> , 15, 319-327	2.2	1
17	Molecular Testing in EBUS-TBNA Specimens of Lung Adenocarcinoma: A Study of Concordance Between Cell Block Method and Liquid-Based Cytology in Appraising Sample Cellularity and EGFR Mutations. <i>Molecular Diagnosis and Therapy</i> , <b>2018</b> , 22, 723-728	4.5	8
16	Treatment Options for EGFR T790M-Negative EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer. <i>Targeted Oncology</i> , <b>2017</b> , 12, 153-161	5	20
15	Are Markers of Systemic Inflammation Good Prognostic Indicators in Colorectal Cancer?. <i>Clinical Colorectal Cancer</i> , <b>2017</b> , 16, 264-274	3.8	56
14	Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies. <i>Drugs in Context</i> , <b>2017</b> , 6, 212506	5.2	6
13	Clinical outcome of EGFR-mutant NSCLC patients continuing TKIs beyond progression in combination with local ablative radiotherapy.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20662-e20662	2.2	
12	Predictive impact of different exon 19 deletions in EGFR-mutant NSCLC treated with first-line TKIs.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e20608-e20608	2.2	
11	From 2000 to 2016: Which Second-Line Treatment in Advanced Non-Small Cell Lung Cancer?. <i>Current Treatment Options in Oncology</i> , <b>2016</b> , 17, 59	5.4	3
10	Gastrointestinal stromal tumors (GISTs) and second malignancies: A novel "sentinel tumor"? A monoinstitutional, STROBE-compliant observational analysis. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4718	1.8	7
9	Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis. <i>Molecular Diagnosis and Therapy</i> , <b>2016</b> , 20, 55-63	4.5	18
8	Maintenance hormonal and chemotherapy treatment in metastatic breast cancer: a systematic review. <i>Future Oncology</i> , <b>2016</b> , 12, 1299-307	3.6	13
7	ERCC1 expression affects outcome in metastatic pancreatic carcinoma treated with FOLFIRINOX: A single institution analysis. <i>Oncotarget</i> , <b>2016</b> , 7, 35159-68	3.3	12
6	Are TKIs favourable for the elderly with non-small-cell lung cancer?. <i>Oncotarget</i> , <b>2016</b> , 7, 46871-46877	3.3	6
5	State of the art of chemotherapy for the treatment of central nervous system metastases from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , <b>2016</b> , 5, 599-609	4.4	15
4	Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease. <i>Clinical Breast Cancer</i> , <b>2015</b> , 15, 307-12	3.2	52

3	Resection of lung metastases from colorectal cancer: Analysis of outcome and prognostic factors.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, e14556-e14556	2.2	
2	Anastrozole-related acute hepatitis with autoimmune features: a case report. <i>BMC Gastroenterology</i> , <b>2011</b> , 11, 32	3	20
1	Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. <i>Gastric Cancer</i> , <b>2007</b> , 10, 104-11	7.6	26